Verubecestat

DB12285InvestigationalSmall molecule

Verubecestat is under investigation for the treatment of Alzheimer's Disease, Prodromal Alzheimer's disease, and Amnestic Mild Cognitive Impairment. Verubecestat is Merck’s investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1... In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat.

Chemical structure of Verubecestat
Mechanism
Curator reviewed
Formula / weight
C17H17F2N5O3S · 409.41 g/mol (avg)
Code names
MK-8931 · SCH-900931

Resolves to

Structure
InChIKeyYHYKUSGACIYRML-KRWDZBQOSA-NSMILESCN1C(N)=N[C@@](C)(CS1(=O)=O)C1=CC(NC(=O)C2=CC=C(F)C=N2)=CC=C1F

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Verubecestat, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account